Companies · Pharmaceuticals

SciSparc Ltd.

TEL AVIV · Pharmaceuticals

Diligence memoA one-page analyst read on SciSparc Ltd. — recommendation, valuation, rhythm, risks.
$25.3M
Total raised · real
5
Rounds
0.8×
Latest step-up
Top 31%
Sector rank · raised
Series A
Latest stage · inferred · Tue Feb 25 2025 00:00:00 GMT+0000 (Coordinated Universal Time)

SciSparc Ltd. looks fair against its niche peers and is quiet on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the pharma sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Fair
  • Modeled value is 1.00× the median modeled value of Series A Pharmaceuticals companies in 2025–2027 (37 peers) — value vs value, same stage and era.
  • Within the normal band (100% of peer median) for its niche.
Quiet
  • Last raise 16 mo ago; this sector typically re-raises about every 13 months.
  • Slightly overdue versus sector cadence.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Pharmaceuticals

SciSparc Ltd. is one of 1613 Pharmaceuticals companies tracked from TEL AVIV. By capital raised it ranks in the upper tier (ahead of 70% of sector peers), and in the long tail by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

As reported in public records reported — not modeled.

US
Jurisdiction
Rule 506(b)
Reg D exemption
4
Investors (latest)
2025-02-25
First sale
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$50M$100M$150M$200MSeed · 2019-04-02 Raised $2.2M (real) Modeled valuation $86M (est)$2.2M$86MSeed2019Seed · 2021-03-01 Raised $3.9M (real) Modeled valuation $104M (est)$3.9M$104MSeed2021Series A · 2022-06-01 Raised $10M (real) Modeled valuation $131M (est)$10M$131MSeries A2022Series A · 2023-10-11 Raised $5.0M (real) Modeled valuation $36M (est)$5.0M$36MSeries A2023Series A · 2025-02-25 Raised $4.2M (real) Modeled valuation $16M (est)$4.2M$16MSeries A2025+$3.9M+$10M+$5.0M+$4.2MCumulative $25M

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Seed$2.2M · 2019
Seed extension$3.9M · 2021
Series A$10.0M · 2022
Series A extension$5.0M · 2023
Series A extension$4.2M · 2025

Stages are modeled from round size (public records carry no series label). No record for: Pre-Seed — the company may have raised it under a different exemption, merged it into an adjacent record, or skipped it. Sequence completeness: 67%.

Modeled valuation trajectory
$16.1M
Base estimate est.
$4.8M
Conservative case
$30.0M
Upside case
$19.1M
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Series Aa $4.0M–$15M round). Valuation is modeled from stage benchmarks scaled by the pharma sector profile. Directional, not a quoted figure.

Seed · modeled $85.6M · 2019-04-022019Seed · modeled $104.3M · 2021-03-01Series A · modeled $131.2M · 2022-06-01Series A · modeled $35.8M · 2023-10-11Series A · modeled $16.1M · 2025-02-252025
Model inputs · modeled:benchmark-stage-stepup-v1
22%
Dilution assumption
Implied ownership sold in the financing.
46%
Survival probability
25% low · 63% high
1.57×/yr
Annual markup
1.97×/yr upside case
1.4 yr
Elapsed time used
1.4 yr actual, capped for stale marks
pharma
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
18 mo
Avg between rounds
$4.3M/yr
Capital velocity
7.3 yr
On record since
2019
First round
5
Rounds on file
How it compares to the market

Benchmarked against 1613 companies in Pharmaceuticals. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages) 3.1× above median
This company$25.3M
Sector median$8.1M
Latest round — vs other Series A rounds in sector (real $, this stage) 0.8× of median
This company$4.2M
Sector median$5.2M
Modeled value — vs sector median (estimate, all stages) 0.2× of median
This company$16.1M
Sector median$76.1M

Raised more than 70% of sector peers (real $). Modeled value above 24% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Series A) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #19 of 37.

This companyCohort peer
$10.0M$100.0M$1.0M$10.0M$100.0MCapital raised (log)Incannex Healthcare Inc. · Series A Raised $12.5M · modeled $47.3M (est)Retension Pharmaceuticals, Inc. · Series A Raised $22.4M · modeled $44.1M (est)Eikonoklastes Therapeutics, Inc. · Series A Raised $25.0M · modeled $43.9M (est)Phoenicis Therapeutics, Inc. · Series A Raised $23.8M · modeled $38.6M (est)Pharmaceutical Resource Technology, Inc. · Series A Raised $10.0M · modeled $37.5M (est)Cristcot LLC · Series A Raised $31.6M · modeled $37.4M (est)Akava Therapeutics Inc. · Series A Raised $30.1M · modeled $37.1M (est)Zetagen Therapeutics, Inc. · Series A Raised $26.1M · modeled $36.6M (est)Biofrontera Inc. · Series A Raised $58.4M · modeled $36.4M (est)D&D Pharmatech Inc. · Series A Raised $10.8M · modeled $36.0M (est)Incyclix Bio, LLC · Series A Raised $26.2M · modeled $35.4M (est)Pharmazz, Inc. · Series A Raised $31.7M · modeled $34.5M (est)SciSparc Ltd. (this company) Raised $25.3M · modeled $16.1M (est)SciSparc Ltd.
CompanyStageRaised · realValue · estvs peer med.
Incannex Healthcare Inc.Series A$12.5M$47.3M2.93×
Retension Pharmaceuticals, Inc.Series A$22.4M$44.1M2.73×
Eikonoklastes Therapeutics, Inc.Series A$25.0M$43.9M2.72×
Phoenicis Therapeutics, Inc.Series A$23.8M$38.6M2.39×
Pharmaceutical Resource Technology, Inc.Series A$10.0M$37.5M2.32×
Cristcot LLCSeries A$31.6M$37.4M2.32×
Akava Therapeutics Inc.Series A$30.1M$37.1M2.30×
Zetagen Therapeutics, Inc.Series A$26.1M$36.6M2.27×
Biofrontera Inc.Series A$58.4M$36.4M2.25×
D&D Pharmatech Inc.Series A$10.8M$36.0M2.23×
Incyclix Bio, LLCSeries A$26.2M$35.4M2.20×
Pharmazz, Inc.Series A$31.7M$34.5M2.14×
SciSparc Ltd. this companySeries A$25.3M$16.1M1.00×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Seed$2.2M2019-04-02$11.2M$85.6M90%
Seed$3.9M2021-03-01$19.4M$104.3M90%
Series A$10.0M2022-06-01$45.5M$131.2M90%
Series A$5.0M2023-10-11$22.8M$35.8M90%
Series A$4.2M2025-02-25$19.1M$16.1M90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Seed$2.2M2019-04-02
    • First recorded raise — entered as Seed.
    • 8 investors on this round.
  2. Seed$3.9M2021-03-01
    • Raised again after 23 mo — slower than the ~13 mo sector norm.
    • Round 1.7× larger than the prior — scaling up.
    • 18 investors on this round.
  3. Series A$10.0M2022-06-01
    • Raised 15 mo later, in step with the ~13 mo sector norm.
    • Round 2.6× larger than the prior — scaling up.
    • 1 investor on this round.
  4. Series A$5.0M2023-10-11
    • Raised 16 mo later, in step with the ~13 mo sector norm.
    • Round 2.0× smaller than the prior — bridge or down round.
    • 1 investor on this round.
  5. Series A$4.2M2025-02-25
    • Raised 17 mo later, in step with the ~13 mo sector norm.
    • Round roughly the size of the prior one.
    • 4 investors on this round.
Intelligence
2026 ~Q3
Modeled next raise · ~18mo cadence
$4.2M
Modeled next size est.range $4.2M$6.7M
0.8×
Last step-up
$4.3M/yr
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
Amitay Weiss5 other2021-03
Eric So4 other2019-04
Oz Adler3 other2019-04
Moshe Revach2 other2021-03
Alon Dayan1 other2021-03
Ascher Shmulewitz1 other2019-04
Dr. Adi Zuloff-Shani1 other2023-10
Stephen Simes1 other2019-04
Zohar Heiblum1 other2019-04
Adi Zuloff-Shani2019-04
Amit Berger2019-04
Amnon Ben Shay2021-03
Itschak Shrem2021-03
Liat Sidi2021-03
Lior Vider2021-03
Yafit Stark2019-04
Registry & provenance

SciSparc Ltd. is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
1611746
SEC CIK
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
Jeffs' Brands LtdRetailingSeries A$7.3M$22.9Mnetwork3 shared operators · same stage
Viewbix Inc.Other TechnologySeries A$9.2M$32.3Mnetwork2 shared operators · same stage
Inspyr Therapeutics, Inc.PharmaceuticalsSeries A$25.6M$12.1Msame sector · same stage
Clearmind Medicine Inc.BiotechnologySeed$2.4M$15.1Mnetwork3 shared operators
Synedgen, Inc.PharmaceuticalsSeries A$24.3M$8.3Msame sector · same stage
Biodexa Pharmaceuticals PlcPharmaceuticalsSeries A$27.1M$25.3Msame sector · same stage
Leafline Labs, LLCPharmaceuticalsSeries A$27.5M$4.6Msame sector · same stage
DemeRx, Inc.PharmaceuticalsSeries A$28.7M$9.0Msame sector · same stage
Semantically similar

Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.

CompanySectorStageValue · estMatch
Scienture Inc.PharmaceuticalsSeries A$185.8M84%
Avant Sciences, Inc.PharmaceuticalsPre-Seed$1.0M83%
Scinai Immunotherapeutics Ltd.PharmaceuticalsSeed$10.5M82%
Cel Sci CorpPharmaceuticalsSeed$57.4M82%
Harmony Biosciences II, Inc.PharmaceuticalsSeries D+$1.8B81%
Rvc 360, LlcPharmaceuticalsSeries A$464.6M80%
Dosentrx Ltd.PharmaceuticalsSeed$3.6M80%
VersaPeutics, Inc.PharmaceuticalsSeed$121.7M80%
Frequently asked
How much funding has SciSparc Ltd. raised?
SciSparc Ltd. has raised approximately $25.3M in disclosed capital across 5 recorded financing rounds, aggregated from public filings.
What is SciSparc Ltd.'s estimated valuation?
Provath's modeled valuation for SciSparc Ltd. is approximately $16.1M (modeled range $4.8M–$30.0M). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is SciSparc Ltd. at?
SciSparc Ltd.'s latest modeled financing stage is Series A. Its most recent recorded round closed around Tue Feb 25.
What does SciSparc Ltd. do and where is it based?
SciSparc Ltd. operates in the Pharmaceuticals sector, based in TEL AVIV.
Explore related

See where SciSparc Ltd. sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at SciSparc Ltd., claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.